SAN DIEGO, June 27 /PRNewswire/ -- Genomatica, Inc., a leading systems biology company addressing metabolism-driven product opportunities, announced today it has entered into an expanded multi-year collaboration and license agreement with DSM, a global supplier of ingredients based on fermentation and enzyme technology to the chemical, pharmaceutical and food industries. This partnership centers round the general implementation of Genomatica’s proprietary metabolic modeling and simulation technologies, capabilities, and expertise to help DSM develop improved biological processes to produce valuable products of interest to DSM. This partnership builds on a previous collaboration between the two companies where Genomatica successfully established the utility of its technology to improve the effectiveness of certain DSM research and development programs.
“We are excited to be expanding our relationship with DSM, one of the largest chemical and biotechnology companies in Europe,” commented Christophe H. Schilling, Ph.D., President and Chief Scientific Officer at Genomatica. “Our research efforts and accomplishments are demonstrating increasing positive impacts for DSM. We believe this momentum will continue as we advance our technology platforms and build toward providing more fully integrated metabolic engineering solutions to DSM and our customers worldwide for developing next generation microbial bio-factories to produce valuable industrial products from sustainable feedstocks.”
“Genomatica offers an ideal combination of State-of-the-art technology and a very professional project management. Their technology package will certainly have a big impact on the continuous need to further improve the performance of our cell-factory based processes,” commented Marco van den Berg, Principal Scientist at DSM.
Financial details of the agreement were not disclosed, but include research and development support, technology license fees, and milestone payments.
About Genomatica
Genomatica is an innovative biotechnology company that possesses proprietary technologies to transform the design, engineering, and manipulation of living cells for the production of valuable biological and chemical products. Genomatica is dedicated to developing and commercializing these high throughput research technologies to address metabolism-driven product opportunities in the chemical, material, energy, pharmaceutical, and other industries. As recognized industry leaders in systems biology with worldwide commercial partnerships, Genomatica is enabling and accelerating the development of its customers’ bio-derived products and research programs. By implementing integrated computational/experimental platforms designed around its advanced award-winning modeling and simulation technologies, Genomatica performs research for its customers to rapidly develop next generation product development processes, and licenses proprietary technologies and intellectual property for use in its partners’ own laboratories. Genomatica is currently pursuing commercial relationships with major industrial biotechnology, chemical, pharmaceutical and energy companies seeking to leverage the power of systems biology for rapid development of biological and chemical products. For more information, please visit us on our website at www.genomatica.com.
Genomatica, Inc.
CONTACT: Christophe H. Schilling, Ph.D., President & Chief ScientificOfficer, or Patricia A. Bladh, Media Relations, or Thomas A. Reed, VicePresident, Finance & Corporate Development, all of Genomatica, Inc.,+1-858-824-1771
Web site: http://www.genomatica.com/
